Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | WDR5 | P61964 | 3/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784161 | 0.90 | ALDH1A1 (0.41) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL783985 | 0.86 | ALDH1A1 (0.48) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL785423 | 0.85 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL784268 | 0.85 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2ALDH1A1CCR5 | |
| SCHEMBL785526 | 0.83 | GBA1 (0.42) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL785226 | 0.83 | GBA1 (0.42) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL784191 | 0.83 | BDKRB1 (0.42) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL784251 | 0.83 | TAF1 (0.41) | ALDH1A1WDR5SPRGBA1USP2 | |
| SCHEMBL785165 | 0.82 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 | |
| SCHEMBL784828 | 0.82 | GBA1 (0.41) | TAS1R3TAS1R1TAS1R2ALDH1A1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TAS1R3 202/4885TAS1R1 75/4885TAS1R2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.